These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21810561)

  • 1. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract.
    Matuschek C; Bölke E; Peiper M; Knoefel WT; Budach W; Erhardt A; Scherer A; Gerber PA; Buhren BA; Gattermann N; Baldus SE; Rusnak E; Shukla V; Orth K
    Eur J Med Res; 2011 Jun; 16(6):265-74. PubMed ID: 21810561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West.
    Wilke H; Lordick F; Meyer HJ; Stahl M
    Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 4. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
    Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
    Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
    Sandler S
    Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
    Ott K; Lordick F
    Chirurg; 2009 Nov; 80(11):1028-34. PubMed ID: 19756431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized surgical strategies for cancer of the esophagogastric junction.
    Stein HJ; Feith M; Siewert JR
    Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
    Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
    Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
    Cohen DJ; Leichman L
    J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment approaches to esophagogastric junction tumors.
    Kurokawa Y; Sasako M; Doki Y
    Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siewert III Adenocarcinoma: Still Searching for the Right Treatment Combination.
    Tang A; Sohal D; McNamara M; Murthy SC; Raja S
    Surg Oncol Clin N Am; 2020 Oct; 29(4):647-653. PubMed ID: 32883464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?
    Moorcraft SY; Smyth EC; Cunningham D
    Gastric Cancer; 2015 Jan; 18(1):1-10. PubMed ID: 24638977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy].
    Semrau R; Vallböhmer D; Hölscher AH; Müller RP
    Chirurg; 2009 Nov; 80(11):1035-41. PubMed ID: 19820906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
    Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
    Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
    Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
    Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.